A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallel-group, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del CFTR Mutation
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 05 Jul 2017 Planned End Date changed from 1 Dec 2018 to 1 Aug 2017.
- 05 Jul 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2017.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.